TriangleSelinexor Maintenance (NCT07200102)
Selinexor Maintenance trial for Relapsed Multiple Myeloma After CAR T-Cell Therapy (NCT07200102). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with multiple myeloma that came back after earlier treatment and who are getting CAR T cell therapy.
The idea: CAR T cells are a patient's own immune cells, reprogrammed to attack myeloma. There is no standard treatment to keep the cancer away afterward. This study adds selinexor, a pill that blocks a protein called XPO1, as maintenance after the CAR T infusion, for up to twelve cycles.
The study looks at safety and whether patients can stay on it.
This phase 1 study plans 20 patients. At Washington University School of Medicine in St. Louis, Mark Schroeder leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.